The concentration of memantine in the cerebrospinal fluid of Alzheimer´s disease patients and its consequence to oxidative stress biomarkers
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60162694%3AG44__%2F19%3A00537046" target="_blank" >RIV/60162694:G44__/19:00537046 - isvavai.cz</a>
Alternative codes found
RIV/00179906:_____/19:10398436 RIV/00216208:11130/19:10398436 RIV/00216208:11150/19:10398436 RIV/00216208:11160/19:10398436 and 2 more
Result on the web
<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00943/full" target="_blank" >https://www.frontiersin.org/articles/10.3389/fphar.2019.00943/full</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3389/fphar.2019.00943" target="_blank" >10.3389/fphar.2019.00943</a>
Alternative languages
Result language
angličtina
Original language name
The concentration of memantine in the cerebrospinal fluid of Alzheimer´s disease patients and its consequence to oxidative stress biomarkers
Original language description
Memantine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist utilized as a palliative cure for Alzheimer's disease. This is the second study examining the memantine concentrations in cerebrospinal fluid. The previously published study enrolled six patients and three of them were theoretically in a steady state. In our study, we enrolled 22 patients who regularly used a standard therapeutic dose of memantine (20 mg per day, oral administration) before the sample collection. Patients were divided into four groups, according to the time of plasma and cerebrospinal fluid collection: 6, 12, 18 and 24 hours after memantine administration. The cerebrospinal fluid samples were also assessed for selected oxidative stress parameters (malondialdehyde, 3-nitrotyrosine, glutathione, non-protein thiols and non-protein disulfides). The plasma/CSF ratio for all time intervals were within the range of 45.89 % (6 hours) - 55.60 % (18 hours), which corresponds with previously published findings in most patients. The other aim of our study was to deduce whether the achieved “real” memantine concentration in the central compartment was sufficient to block NMDA receptors. The IC50 value of memantine as an NMDA antagonist is in micromolar range; the lowest limit is 112 ng/mL (GluN2C), and this value was achieved only in three cases. The memantine cerebrospinal fluid concentration did not reach ¼ of the IC50 value in 5 cases (one patient was excluded for noncompliance); therefore, the potency of memantine as a therapeutic effect in patients may be questionable. However, it appears that memantine therapy positively affected the levels of some oxidative stress parameters, especially non-protein thiols and 3-nitrotyrosine. © 2019 Frontiers Media S.A.. All rights reserved.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy
Result continuities
Project
<a href="/en/project/EF18_069%2F0010054" target="_blank" >EF18_069/0010054: IT4Neuro(degeneration)</a><br>
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Frontiers in Pharmacology
ISSN
1663-9812
e-ISSN
1663-9812
Volume of the periodical
10
Issue of the periodical within the volume
Aug
Country of publishing house
CH - SWITZERLAND
Number of pages
8
Pages from-to
943
UT code for WoS article
000482910900001
EID of the result in the Scopus database
2-s2.0-85070694221